Thursday, November 16, 2017 -- A preference to use CAM before seeking medical advice may be harming patients with inflammatory arthritis.
Friday, November 17, 2017 -- In the quest for a new and more effective treatment for rheumatoid arthritis, researchers from the Keck School of Medicine of USC looked to a primate that mostly roams the land in Asia, the Middle East and Africa.
Monday, November 20, 2017 -- by Ulf Guendisch, Jessica Weiss, Florence Ecoeur, Julia Christina Riker, Klemens Kaupmann, Joerg Kallen, Samuel Hintermann, David Orain, Janet Dawson, Andreas Billich, Christine Guntermann Retinoic acid receptor-related-orphan-receptor-C (RORγt) is the key transcription factor that is driving the differentiation of IL-17 producing T-helper 17 (Th17) cells that are implicated in the pathology of various autoimmune and inflammatory diseases. Based on the importance of RORγt in promoting Th17-driven pathology, there is considerable interest to develop low-molecular-weight compounds with the aim of inhibiting the transcriptional activity of this nuclear hormone receptor. In this article, we describe the in vitro and in vivo pharmacology of a potent and selective small-molecular-weight RORγt inverse agonist. The compound binds to the ligand binding domain (LBD) of
Monday, November 20, 2017 -- by Yi-Ming Chen, Hsin-Hua Chen, Wen-Nan Huang, Tsai-Ling Liao, Jun-Peng Chen, Wen-Cheng Chao, Ching-Tsai Lin, Wei-Ting Hung, Chia-Wei Hsieh, Tsu-Yi Hsieh, Yi-Hsing Chen, Der-Yuan Chen Rheumatoid arthritis (RA) is associated with a high risk of osteoporosis and fracture. Interleukin (IL)-6 inhibitors may suppress osteoclast activation. Anticitrullinated protein antibody (ACPA) titers are inversely associated with bone mineral density (BMD). However, the differential effect of ACPA on bone turnover marker (BTM) and BMD changes after IL-6 inhibition remains unclear. This prospective study recruited patients with active RA with inadequate response to methotrexate or biologics. BMD was measured before and after 2-year tocilizumab (TCZ) treatment. Serum osteocalcin, N-terminal propeptide of type I collagen (P1NP), and C-terminal cross-linking telopeptide of type I collagen
Thursday, November 16, 2017 -- The device has 14 pre-set therapy modes designed to block acute or chronic pain or to imitate exercise recovery, endurance and muscle strength.
Monday, November 20, 2017 -- Zilretta is the first extended-release, intra-articular injection for OA knee pain.
Friday, November 17, 2017 -- Administration of abatacept may improve patient-reported outcomes in individuals with active psoriatic arthritis and elevated levels of C-reactive protein, irrespective of tumor necrosis factor inhibitor treatment history.
Friday, November 17, 2017 -- Inflammation shown on MRI of the sacroiliac joint (MRI-SI) is prevalent in axSpA (±30%), but the specificity is not well known.
Friday, November 17, 2017 -- The guideline includes recommendations for treating adult patients with active psoriatic arthritis.
Friday, November 17, 2017 -- Researchers found that HLA status was associated with gut microbiota diversity.
Monday, November 20, 2017 -- Individuals with osteoarthritis may exhibit a higher prevalence of sarcopenic obesity, compared with patients with rheumatoid arthritis.
Monday, November 20, 2017 -- Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.
Thursday, November 16, 2017 -- Clinicians conducting pneumococcal vaccination in patients with rheumatoid arthritis should take into consideration the type of RA treatment being used and offer early vaccination.
Monday, November 20, 2017 -- This tool may be used to reduce stressors, improve well-being, and decrease symptoms.
Monday, November 20, 2017 -- NewsErgonomically designed reusable autoinjector provides an additional administration option for Enbrel (etanercept) users. The new Enbrel Mini with AutoTouch was approved by the FDA in September 2017. Contributed Author: AmgenTopics: Enterprise Technology